Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia

被引:44
作者
Caraceni, P. [1 ]
Pertosa, A. M. [1 ]
Giannone, F. [1 ]
Domenicali, M. [1 ]
Grattagliano, I. [2 ]
Principe, A. [1 ]
Mastroleo, C. [1 ]
Perrelli, M. G. [3 ]
Cutrin, J. [3 ]
Trevisani, F. [1 ]
Croci, T. [4 ]
Bernardi, M. [1 ]
机构
[1] Univ Bologna, Dept Clin Med, I-40138 Bologna, Italy
[2] Univ Bari, Dept Clin & Publ Med, I-70121 Bari, Italy
[3] Univ Turin, Dept Expt Pathol, I-10124 Turin, Italy
[4] Sanofi Aventis Res Labs, Milan, Italy
关键词
HEPATIC ISCHEMIA/REPERFUSION INJURY; ENDOCANNABINOID SYSTEM; INTERFERON-GAMMA; CB1; RECEPTORS; IN-VITRO; MECHANISMS; LIPOPOLYSACCHARIDE; SUPPRESSORS; INCREASES; CYTOKINES;
D O I
10.1136/gut.2007.147652
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/aim: Endotoxaemia can complicate hepatic ischaemia-reperfusion (IR) injury. Endocannabinoids appear to modulate the haemodynamic alterations and cytokine response induced by lipopolysaccharide (LPS). Thus, we aimed to determine the effect of the endocannabinoid CB1-receptor antagonist Rimonabant in a model of hepatic IR injury complicated by endotoxaemia. Methods: Sprague-Dawley rats pre-treated with Rimonabant 3 or 10 mg/kg or vehicle underwent partial hepatic IR and lipopolysaccharide (LPS) injection at reperfusion. Liver injury was evaluated by serum alanine aminotransferase (ALT) and necrotic-cell count. The inflammatory response was investigated by assessing hepatic neutrophil infiltration, tumour necrosis factor alpha (TNF alpha), interferon gamma (IFN gamma), interleukin 6 (IL6), and suppressor of cytokine signalling (SOCS) 1 and SOCS3 gene expression by real-time polymerase chain reaction (RT-PCR). Systolic blood pressure and hepatic blood flow were measured as haemodynamic parameters. Finally, lipid peroxidation, glutathione status, and immunoreactive CB1 receptor expression in the liver were also determined. Results: Liver injury and neutrophil infiltration occurring in the late-phase of LPS-enhanced IR were significantly reduced by CB1-receptor antagonism. Rimonabant-treated rats showed significantly higher gene expression of IFN gamma, IL6, SOCS1 and SOCS3 in "early'' reperfusion, while that of TNF alpha was reduced. These findings were associated with increased STAT3 phosphorylation. Furthermore, CB1-receptor antagonism significantly improved the oxidative injury and haemodynamic alterations occurring during reperfusion in untreated rats. Finally, CB1-receptor immunoreactivity was upregulated early after reperfusion. Conclusions: This study demonstrates that CB1-receptor antagonism protects the liver against LPS-enhanced IR injury by interfering with the inflammatory response that causes the late, neutrophil-dependent phase of reperfusion injury, although the prevention of the transient endotoxin-related hypotension occurring early during reperfusion may be also involved.
引用
收藏
页码:1135 / 1143
页数:9
相关论文
共 43 条
[1]   Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction [J].
Alexander, WS ;
Starr, R ;
Metcalf, D ;
Nicholson, SE ;
Farley, A ;
Elefanty, AG ;
Brysha, M ;
Kile, BT ;
Richardson, R ;
Baca, M ;
Zhang, JG ;
Willson, TA ;
Viney, EM ;
Sprigg, NS ;
Rakar, S ;
Corbin, J ;
Mifsud, S ;
DiRago, L ;
Cary, D ;
Nicola, NA ;
Hilton, DJ .
JOURNAL OF LEUKOCYTE BIOLOGY, 1999, 66 (04) :588-592
[2]   Endocannabinoids acting at vascular CB, receptors mediate the vasodilated state in advanced liver cirrhosis [J].
Bátkai, S ;
Járat, Z ;
Wagner, JA ;
Goparaju, SK ;
Varga, K ;
Liu, J ;
Wang, L ;
Mirshahi, F ;
Khanolkar, AD ;
Makriyannis, A ;
Urbaschek, R ;
Garcia, N ;
Sanyal, AJ ;
Kunos, G .
NATURE MEDICINE, 2001, 7 (07) :827-832
[3]   Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury [J].
Batkai, Sandor ;
Osei-Hyiaman, Douglas ;
Pan, Hao ;
El-Assal, Osama ;
Rajesh, Mohanraj ;
Mukhopadhyay, Partha ;
Hong, Feng ;
Harvey-White, Judith ;
Jafri, Anjum ;
Hasko, Gyorgy ;
Huffman, John W. ;
Gao, Bin ;
Kunos, George ;
Pacher, Pal .
FASEB JOURNAL, 2007, 21 (08) :1788-1800
[4]   Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury [J].
Bertini, R ;
Allegretti, M ;
Bizzarri, C ;
Moriconi, A ;
Locati, M ;
Zampella, G ;
Cervellera, MN ;
Di Cioccio, V ;
Cesta, MC ;
Galliera, E ;
Martinez, FO ;
Di Bitondo, R ;
Troiani, G ;
Sabbatini, V ;
D'Anniballe, G ;
Anacardio, R ;
Cutrin, JC ;
Cavalieri, B ;
Mainiero, F ;
Strippoli, R ;
Villa, P ;
Di Girolamo, M ;
Martin, F ;
Gentile, M ;
Santoni, A ;
Corda, D ;
Poli, G ;
Mantovani, A ;
Ghezzi, P ;
Colotta, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) :11791-11796
[5]   Suppressor of cytokine signaling-1 attenuates the duration of interferon γ signal transduction in vitro and in vivo [J].
Brysha, M ;
Zhang, JG ;
Bertolino, P ;
Corbin, JE ;
Alexander, WS ;
Nicola, NA ;
Hilton, DJ ;
Starr, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22086-22089
[6]   Intramucosal pH and serum endotoxin concentrations as early predictive parameters for primary nonfunction after experimental liver transplantation [J].
Bud, O ;
Golling, M ;
von Frankenberg, M ;
Mehrabi, A ;
Kraus, T ;
Urbaschek, R ;
Gebhard, MM ;
Herfarth, C ;
Klar, E .
TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) :2537-2538
[7]   Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent [J].
Camargo, CA ;
Madden, JF ;
Gao, WS ;
Selvan, RS ;
Clavien, PA .
HEPATOLOGY, 1997, 26 (06) :1513-1520
[8]  
Chieco P., 2001, Image Cytometry
[9]   Lung and liver injury following hepatic ischemia/reperfusion in the rat is increased by exogenous lipopolysaccharide which also increases hepatic TNF production in vivo and in vitro [J].
Colletti, LM ;
Green, M .
SHOCK, 2001, 16 (04) :312-319
[10]   Role of cannabinoid CB1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents [J].
Croci, T ;
Landi, M ;
Galzin, AM ;
Marini, P .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (01) :115-122